
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) stock is trading lower on Friday, with a session volume of 4.695 million, as per data from Benzinga Pro.
On Thursday, during after-hours trading, the company said it regained full rights to its lead TSHA-102 program in clinical evaluation for Rett syndrome.